Company news
ChemoCentryx Inc. news in 2020
ChemoCentryx Inc.'s news releases, calls and decks from 2020, newest first.
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
December 20, 2020
ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights
November 8, 2020
ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
November 5, 2020
ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)
October 27, 2020
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
September 16, 2020
ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights
August 9, 2020
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
July 8, 2020
ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
June 23, 2020
ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
June 14, 2020
ChemoCentryx Prices Public Offering of Common Stock
June 9, 2020
ChemoCentryx Announces Proposed Public Offering of Common Stock
June 9, 2020
ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
May 17, 2020
ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights
May 10, 2020
ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital
January 8, 2020
Calls in 2020
Decks in 2020
- Investor Presentation (January 2020)
Investor deck · 38 slides · Jan 16, 2020